Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Published April 22, 2025
Citation Information: JCI Insight. 2025;10(11):e186747. https://doi.org/10.1172/jci.insight.186747.
View: Text | PDF
Research Article Cell biology Clinical Research Genetics

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor

  • Text
  • PDF
Abstract

Mutations in genome maintenance factors drive sporadic and hereditary breast cancers. Here, we searched for potential drivers based on germline DNA analysis from a cohort consisting of patients with early-onset breast cancer negative for BRCA1/BRCA2 mutations. This revealed candidate genes that subsequently were subjected to RNA interference–based (RNAi-based) phenotype screens to reveal genome integrity effects. We identified several genes with functional roles in genome maintenance, including Glucose-6-Phosphatase Catalytic Subunit 3 (G6PC3), SMC4, and CCDC108. Notably, G6PC3-deficient cells exhibited increased levels of γH2AX and micronuclei formation, along with defects in homologous recombination (HR) repair. Consistent with these observations, G6PC3 was required for the efficient recruitment of BRCA1 to sites of DNA double-strand breaks (DSBs). RNA-Seq analysis revealed that G6PC3 promotes the expression of multiple homologous recombination repair genes, including BRCA1. Through CRISPR-Select functional-genetic phenotype analysis of G6PC3 germline mutations, we identified 2 germline G6PC3 variants displaying partial loss of function. Furthermore, our study demonstrated that G6pc3 deficiency accelerates mammary tumor formation induced by Trp53 loss in mice. In conclusion, our cohort-based functional analysis has unveiled genome maintenance factors and identified G6PC3 as a potential candidate tumor suppressor in breast cancer.

Authors

Xin Li, Maria Rossing, Ana Moisés da Silva, Muthiah Bose, Thorkell Gudjónsson, Jan Benada, Jayashree Thatte, Jens Vilstrup Johansen, Judit Börcsök, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Asma Tajik, Lucía Sena, Zoltan Szallasi, Morten Frödin, Jos Jonkers, Finn Cilius Nielsen, Claus Storgaard Sørensen

×

Figure 4

G6PC3 promotes transcription of HRR genes.

Options: View larger image (or click on image) Download as PowerPoint
G6PC3 promotes transcription of HRR genes.
(A) Representative Western bl...
(A) Representative Western blots for BRCA1 expression. U2OS cells were transfected by different siRNA, and the lysate was collected 48 hours afterward. Endogenous actin was used as a loading control. (B) qPCR was used to determine BRCA1 aberrant expression. U2OS cells were transfected with different siRNA for 48 hours. Bar plot indicates means ± SD from 3 biological replicates; statistical significance of differences was evaluated using 1-way ANOVA followed by Dunnett’s test. ***P < 0.001. (C) Validation of effective G6PC3 siRNA knockdown from RNA-Seq datasets. Bar plot representing the DESeq2-normalized G6PC3 counts in each U2OS sample used for RNA-Seq analysis. (D) PCA plot for top 500 variable genes across all samples. (E) GSEA of top 20 upregulated and downregulated pathways after G6PC3 siRNA depletion (q < 0.1). The y axis represents KEGG pathways; the x axis represents the normalized enrichment score (NES) for each pathway. (F) Heatmap illustrates differential expressed HR genes between G6PC3 and control siRNA-treated U2OS cells. Twenty-six downregulated HR genes after G6PC3 depletion are annotated in the figure. The heatmap is colored according to the z score of each gene normalized by row. (G) Analysis of HR pathway (KEGG). The genes are colored according to their log2FC between G6PC3 and control siRNA treated U2OS from the DESeq2 statistical analysis. PCA, Principal component analysis; GSEA, gene set enrichment analysis.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts